Authorized purpose: Analyze fetal ultrasound images and clips to automatically detect views, detect anatomical structures within views, and verify view-quality criteria as a concurrent reading aid during acquisition and interpretation.
Clinical role
Concurrent acquisition and interpretation support that labels views, detects structures, verifies quality criteria, and lets the healthcare professional review or override assignments and verification status.
Images and patients
Ultrasound · Fetus and fetal anatomy
Key limitation
Keep in mind: The FDA packet states that Sonio Detect was validated and is intended only for GE, Canon, and Samsung ultrasound devices. Performance statements apply to the tested view, structure, annotation, and quality-criterion endpoints, including only some views and structures, not to an unrestricted fetal-ultrasound claim.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Analyze fetal ultrasound images and clips to automatically detect views, detect anatomical structures within views, and verify view-quality criteria as a concurrent reading aid during acquisition and interpretation.
Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Fetus and fetal anatomy Input: Fetal ultrasound images and clips received from an ultrasound machine through the Edge Software; the FDA description covers first-, second-, and third-trimester examinations and real-time processing.
Who uses it?Intended users: Qualified and trained healthcare professionals in prenatal ultrasound, including sonographers, maternal-fetal-medicine specialists, OB/GYNs, and fetal surgeons.
What does the software produce?Output: Automatically detected views, anatomical structures within supported views, and verified or not-verified standardized quality criteria, including structure presence/absence and zoom level; users can reassign or edit the results.
What is its most important limitation?Key limitation: The FDA packet states that Sonio Detect was validated and is intended only for GE, Canon, and Samsung ultrasound devices. Performance statements apply to the tested view, structure, annotation, and quality-criterion endpoints, including only some views and structures, not to an unrestricted fetal-ultrasound claim.
Clinical takeaway. Clinical role: Analyze fetal ultrasound images and clips to automatically detect views, detect anatomical structures within views, and verify view-quality criteria as a concurrent reading aid during acquisition and interpretation.
Evidence takeaway. Evidence from the reviewed source record: Standalone bench testing used 17,885 fetal-ultrasound images from seven clinical sites in the United States, France, and Germany, independent of model-development data. Reported endpoints included 3D-image detection sensitivity 0.980 (95% Wilson CI 0.930-0.994), Doppler-image sensitivity 0.963 (0.908-0.985), annotation-reading proportion correct 0.923 (0.905-0.938), some T1-view sensitivity 0.942, some T2/T3-view sensitivity 0.919, fetal-brain structure sensitivity/specificity 0.857/0.963, fetal-heart structure sensitivity/specificity 0.900/0.982, and brain-view zoom sensitivity/specificity 0.952/0.906 (95% Wilson CIs 0.909-0.976 and 0.758-0.968). Clinical studies were stated to be not applicable for substantial equivalence.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Analyze fetal ultrasound images and clips to automatically detect views, detect anatomical structures within views, and verify view-quality criteria as a concurrent reading aid during acquisition and interpretation.
Concurrent acquisition and interpretation support that labels views, detects structures, verifies quality criteria, and lets the healthcare professional review or override assignments and verification status.
Fetal ultrasound images and clips received from an ultrasound machine through the Edge Software; the FDA description covers first-, second-, and third-trimester examinations and real-time processing.
Automatically detected views, anatomical structures within supported views, and verified or not-verified standardized quality criteria, including structure presence/absence and zoom level; users can reassign or edit the results.
Professional prenatal ultrasound imaging environment across first, second, and third trimesters; the FDA device description states a gestational-age range of 11-37 weeks and does not specify a facility type.
Qualified and trained healthcare professionals in prenatal ultrasound, including sonographers, maternal-fetal-medicine specialists, OB/GYNs, and fetal surgeons.
The FDA packet states that Sonio Detect was validated and is intended only for GE, Canon, and Samsung ultrasound devices. Performance statements apply to the tested view, structure, annotation, and quality-criterion endpoints, including only some views and structures, not to an unrestricted fetal-ultrasound claim.
Standalone bench testing used 17,885 fetal-ultrasound images from seven clinical sites in the United States, France, and Germany, independent of model-development data. Reported endpoints included 3D-image detection sensitivity 0.980 (95% Wilson CI 0.930-0.994), Doppler-image sensitivity 0.963 (0.908-0.985), annotation-reading proportion correct 0.923 (0.905-0.938), some T1-view sensitivity 0.942, some T2/T3-view sensitivity 0.919, fetal-brain structure sensitivity/specificity 0.857/0.963, fetal-heart structure sensitivity/specificity 0.900/0.982, and brain-view zoom sensitivity/specificity 0.952/0.906 (95% Wilson CIs 0.909-0.976 and 0.758-0.968). Clinical studies were stated to be not applicable for substantial equivalence.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Standalone bench testing used 17,885 fetal-ultrasound images from seven clinical sites in the United States, France, and Germany, independent of model-development data. Reported endpoints included 3D-image detection sensitivity 0.980 (95% Wilson CI 0.930-0.994), Doppler-image sensitivity 0.963 (0.908-0.985), annotation-reading proportion correct 0.923 (0.905-0.938), some T1-view sensitivity 0.942, some T2/T3-view sensitivity 0.919, fetal-brain structure sensitivity/specificity 0.857/0.963, fetal-heart structure sensitivity/specificity 0.900/0.982, and brain-view zoom sensitivity/specificity 0.952/0.906 (95% Wilson CIs 0.909-0.976 and 0.758-0.968). Clinical studies were stated to be not applicable for substantial equivalence.
FDA endpoint-specific sensitivity: 3D fetal-ultrasound image detection 0.980 (95% Wilson CI 0.930-0.994); Doppler image detection 0.963 (0.908-0.985); some T1 views 0.942 point estimate; some T2/T3 views 0.919 point estimate; some fetal-brain structures 0.857 point estimate; some fetal-heart structures 0.900 point estimate; brain-view zoom verification 0.952 (95% Wilson CI 0.909-0.976).
FDA source
Exact FDA submission
Checked 2026-09-09
The FDA reports multiple view-, image-type-, structure-, and quality-criterion sensitivities; the baseline's isolated 0.980 value is not a device-wide endpoint.
FDA endpoint-specific specificity: some fetal-brain structures 0.963 point estimate; some fetal-heart structures 0.982 point estimate; brain-view zoom verification 0.906 (95% Wilson CI 0.758-0.968).
FDA source
Exact FDA submission
Checked 2026-09-09
Specificity is reported only for bounded structure and zoom-quality endpoints; annotation-reading proportion correct and view-detection sensitivities are separate measures.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Sonio Detect regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K230365
Samplen=17885
Sites7
IndependenceIndependence not established
K230365
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K230365. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Fetal ultrasound images and clips received from an ultrasound machine through the Edge Software; the FDA description covers first-, second-, and third-trimester examinations and real-time processing.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA description states that Edge Software runs on a server on the same network as the ultrasound machine, receives DICOM instances, uploads them to Sonio Cloud, and provides SaaS access through an internet browser; exact current interfaces and local compatibility are not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes Sonio Detect as a Software as a Service solution accessed from an internet browser, with Edge Software installed on a server on the same network as the ultrasound machine that uploads DICOM instances to Sonio's Cloud. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Sonio Detect is a Software as a Service SaaS solution that aims at helping sonographers," … "Edge Software (described below) to install on a server on the same network as the Ultrasound Machine; ● SaaS accessibility from internet browser.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Automatically detected views, anatomical structures within supported views, and verified or not-verified standardized quality criteria, including structure presence/absence and zoom level; users can reassign or edit the results.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Automatically detected views, anatomical structures within supported views, and verified or not-verified standardized quality criteria, including structure presence/absence and zoom level; users can reassign or edit the results.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes Sonio Detect as a Software as a Service solution accessed from an internet browser, with Edge Software installed on a server on the same network as the ultrasound machine that uploads DICOM instances to Sonio's Cloud. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Sonio Detect is a Software as a Service SaaS solution that aims at helping sonographers," … "Edge Software (described below) to install on a server on the same network as the Ultrasound Machine; ● SaaS accessibility from internet browser.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The FDA description states that Edge Software runs on a server on the same network as the ultrasound machine, receives DICOM instances, uploads them to Sonio Cloud, and provides SaaS access through an internet browser; exact current interfaces and local compatibility are not established.
Sonio's security page states HIPAA and GDPR compliance, HDS-certified cloud providers, SOC 2 Type 2 compliance, encryption at rest and in transit, a web application firewall with intrusion detection, and isolated regional deployments. Vendor-wide.
Vendor-wide
Checked 2026-10-25
Vendor statement, not an attestation; exact-release scope is not established.
ACR AI Central provides an exact-submission model card for Sonio Detect; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K230365 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Assist qualified MSK-ultrasound professionals by highlighting supported joint anatomy and detection completeness on compatible adult ultrasound images; it is not a diagnostic device.
Modality
Ultrasound
Anatomy
Musculoskeletal joints: shoulder, elbow, wrist/hand, knee, and ankle/foot.
Authorized purpose: Sonio Detect v3 analyzes fetal ultrasound images and clips to detect views and anatomical structures and to check labeled image-quality characteristics during acquisition or interpretation.
Authorized purpose: BioticsAI assists healthcare professionals during and after fetal ultrasound acquisition and interpretation by detecting views and anatomical structures and facilitating quality-criteria verification on DICOM images and frames; it is a concurrent reading aid for the labeled GE ultrasound and prenatal population.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.